Definium Therapeutics, Inc. (DFTX) Earnings Call Transcripts

Definium Therapeutics, Inc.'s Latest Earnings Call - June 22, 2026

Definium Therapeutics, Inc. reported significant top-line results from its Phase III Emerge study for DT120 ODT, a treatment for major depressive disorder (MDD). The study met all primary and key secondary endpoints, demonstrating an 8.1-point placebo-adjusted improvement on the MADRS at week 6, with a p-value of less than 0.0001. The results exceeded expectations, positioning DT120 ODT as a potentially best-in-class treatment. Management expressed optimism about the future, citing upcoming Phase III readouts and the potential for DT120 ODT to reshape treatment paradigms in psychiatry. No changes to revenue or earnings guidance were provided, as the focus remains on clinical results and regulatory pathways.

Reported metrics

Guidance from management

Management did not provide specific revenue or earnings guidance but expressed strong confidence in the upcoming Phase III readouts and the potential for DT120 ODT to reshape treatment paradigms in psychiatry.

What management said

I agree with all of that. I mean the product profiles that we've tested market research, the data exceeds what has been tested to date. So there's more evidence to collect in market to understand how physicians and payers will react to it. But the data does open the opportunity for earlier line treatment downstream, as Rob said, and we're very excited about that.

I think to a larger point as well, when you have a magnitude of effect as large as what we've seen here in a study of this size, it's really unlikely that you're going to find any subgroup that was somehow the fundamental driver of that. I mean a magnitude of mean effect of this size kind of has to be a population effect. And so we're really confident that this outcome represents our ability to move this scale across...

What analysts pressed on

Analysts raised questions about the implications of the study results for regulatory approval and market positioning. Concerns were also expressed regarding the long-term retreatment data and the potential for DT120 ODT to be used as a frontline treatment.

Main topics on the call

• Emerge Study Results — The Phase III Emerge study demonstrated an 8.1-point placebo-adjusted improvement on the MADRS at week 6, with a p-value of less than 0.0001. Management stated, "Today's results far exceeded those expectations with effic...
• Durability of Efficacy — The efficacy of DT120 ODT was sustained with a 7.3-point placebo-adjusted improvement observed at week 12. Management highlighted that "this staggering effect was durable for the full duration of Part A," reinforcing the...
• Safety Profile — DT120 ODT was well tolerated, with no serious adverse events reported and no suicidality signals observed. Management noted, "99% of adverse events were mild to moderate in severity," suggesting a favorable safety profil...
• Regulatory Pathway and Future Studies — Management is optimistic about upcoming Phase III readouts for GAD and the potential for DT120 ODT to receive regulatory approval. They stated, "We see two distinct drivers of this value creation opportunity," indicating...

Read the full Definium Therapeutics, Inc. transcript (June 22, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 28 Definium Therapeutics, Inc. earnings call transcripts on record, spanning April 1, 2020 to August 6, 2026. Based on this history, Definium Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DFTX

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

28

First call

April 1, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly